论文部分内容阅读
目的观察莫西沙星注射液治疗重症社区获得性肺炎的临床疗效。方法将符合入选条件的60例重症社区获得性肺炎患者分为治疗组和对照组,每组30例,两组基础治疗相似,治疗组患者予莫西沙星注射液250ml,静脉点滴,每天1次,共6d;对照组30例,予注射用头孢曲松钠2.0g加入0.9%氯化钠注射液250 mL,静脉点滴,每天1次,共6d。6d后,根据病情决定是否继续进行抗生素治疗。分别给予治疗前后临床疗效比较,同时检测治疗前、后的血常规及痰培养等。结果治疗组疗效(80%)明显优于对照组(60%),差异有统计学意义(P<0.05),且无不良反应。结论莫西沙星注射液治疗重症社区获得性肺炎疗效确切,安全可靠。
Objective To observe the clinical efficacy of moxifloxacin injection in the treatment of severe community-acquired pneumonia. Methods Sixty patients with severe community-acquired pneumonia who met the inclusion criteria were divided into treatment group and control group, with 30 cases in each group. The basic treatment was similar in both groups. The treatment group received 250ml moxifloxacin injection intravenously once a day , A total of 6d; the control group of 30 patients were injected with ceftriaxone 2.0g 0.9% sodium chloride injection 250 mL intravenously once a day for 6 days. After 6d, according to the condition decide whether to continue antibiotic treatment. Respectively, before and after treatment to compare the clinical efficacy, while testing before and after treatment of blood and sputum culture. Results The treatment group (80%) was significantly better than the control group (60%), the difference was statistically significant (P <0.05), and no adverse reactions. Conclusion Moxifloxacin injection is effective and safe for the treatment of severe community-acquired pneumonia.